Mivacron (Mivacurium Chloride)

Mivacurium chloride competitively blocks nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine‑induced depolarization of skeletal muscle fibers. This inhibition stops nerve‑muscle transmission, producing rapid and reversible muscle relaxation.

The dose of Mivacron is individualized by the prescribing clinician based on patient weight, age, hepatic function, and the specific clinical situation. No fixed regimen is provided here; dosing decisions are made by qualified healthcare professionals.

The pregnancy category for mivacurium chloride is listed as unknown. Use during pregnancy or lactation should only occur when the potential benefit outweighs any possible risk, and it must be decided by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Mivacron is a short‑acting, non‑depolarizing blocker that is rapidly hydrolyzed by plasma cholinesterase, offering a quicker recovery than longer‑acting agents such as rocuronium or vecuronium. Its onset is comparable to other agents, but its brief duration makes it useful for short procedures or when rapid reversal is desired.

Mivacron should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and discard any solution that appears discolored or contains particles.

Mivacron is supplied as an injectable solution for intravenous use. It is administered as a bolus dose, often followed by a continuous infusion if prolonged muscle relaxation is required, under continuous neuromuscular monitoring.

Serious risks include prolonged neuromuscular blockade that may necessitate extended mechanical ventilation, severe hypotension or cardiovascular collapse, anaphylactic reactions, and rare occurrences of hyperkalemia. Prompt recognition and appropriate supportive measures are essential.

Mivacron should be avoided in patients with known hypersensitivity to mivacurium or related compounds, and used with caution in individuals with significant hepatic impairment, severe electrolyte disturbances, or those receiving interacting drugs such as aminoglycosides, lithium, or magnesium sulfate.